CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-12-29): Tenofovir plus emtricitabine shows efficacy in resistant HBV infection

Clinical

Tenofovir plus emtricitabine shows efficacy in resistant HBV infection

Last Updated: 2006-12-29 16:00:21 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A switch from adefovir to tenofovir plus emtricitabine may achieve undetectable viral levels in chronic hepatitis B virus (HBV) infection when an adefovir-containing regimen fails, investigators at Mount Sinai School of Medicine in New York report.

In a study published in the December issue of the European Journal of Gastroenterology and Hepatology, Dr. Stephanie A. Santos and colleagues describe seven patients with chronic HBV infection who failed to achieve undetectable levels of HBV DNA on adefovir or an adefovir-containing regimen.

Patients were all HIV- seronegative. They had been on adefovir for a mean of ten months at enrollment and median HBV DNA was 430,000 copies/ml with a median fall in HBV DNA of 2.0 log10copies/ml.

Dr. Santos' team changed treatment to tenofovir, 300 mg daily, and emtricitabine, 200 mg daily.

After a median treatment duration of 23 months with tenofovir, the HBV DNA fall was 3.0 log10copies/ml.

All seven patients achieved undetectable HBV DNA levels with tenofovir. Anti-hepatitis B e seroconversion occurred in one patient.

There were no significant changes in serum creatinine levels and none of the patients reported serious adverse effects.

"Given the possibility of significant morbidity and mortality with hepatitis B, it is imperative that new treatment options be explored," the investigators point out. "It has been shown that lower levels of HBV DNA correlate with an improved histologic, biochemical and serologic response."

While adefovir is the treatment of choice for chronic HBV infection, resistance develops in more than one-quarter of patients, the authors write. The response in this series of patients to tenofovir after treatment failure with adefovir indicates that it may be an effective option for patients with resistant HBV infection.

Eur J Gastroenterol Hepatol 2006;18:1247-1253.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.